Vanda Pharmaceuticals Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$4.6
Valuation models combined (2)
Base case. Range ~$3.7–$8.1. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.
No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.
Vanda Pharmaceuticals Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Model value −32.3%
Revenue for the twelve months to September 2026 was $229m, up 8.1% on a year earlier, faster than the 6.0% growth a quarter earlier. Free-cash-flow margin fell to -61.0% from -39.1% a year earlier. Operating margin narrowed to -77.6% from -57.1%. Our model value falls from $9.19 to $6.22 a share, against a share price of $3.79.
Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation
Revenue for the twelve months to June 2026 was $229m, up 8.1% on a year earlier, faster than the 6.0% growth a quarter earlier. Free-cash-flow margin fell to -61.0% from -39.1% a year earlier. Operating margin narrowed to -77.6% from -57.1%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $9.19 a share.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Vanda Pharmaceuticals Inc.'s trailing-twelve-month revenue grew 8.1% year on year, with a free-cash-flow margin of -61.0%. Where it lags: free-cash-flow margin of -61.0% ranks 63 of 74 pharmaceuticals companies we cover.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 68.7% while net income fell 226.4%: a 158pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Vanda Pharmaceuticals Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.82 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$3.7 ~$0.7–$6.3 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$8.1 ~$7.1–$20 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$4.6 ~$3.7–$8.1 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Vanda Pharmaceuticals Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $9.31 | $15.95 | $15.20 | $26.13 | $16.41 | $13.14 | $15.69 | $7.39 | $4.22 | $4.79 | $8.82 | $3.88 |
| Market value | $393m | $693m | $680m | $1.4bn | $900m | $725m | $893m | $421m | $243m | $279m | $520m | $232m |
| + Net debt (− = net cash) | −$51m | −$40m | −$34m | −$61m | −$45m | −$61m | −$52m | −$135m | −$136m | −$102m | −$85m | −$62m |
| Enterprise value | $343m | $653m | $646m | $1.3bn | $855m | $664m | $841m | $286m | $107m | $176m | $435m | $170m |
| Multiples | ||||||||||||
| Price / sales | 3.6x | 4.7x | 4.1x | 7.2x | 4.0x | 2.9x | 3.3x | 1.7x | 1.3x | 1.4x | 2.4x | 1.0x |
| Price / earnings | — | — | — | 55.0x | 7.8x | 31.1x | 26.9x | 67.1x | 96.8x | — | — | — |
| Price / free cash flow | 39.6x | — | — | 46.8x | 20.0x | 14.5x | 14.0x | 13.5x | 19.6x | — | — | — |
| EV / EBITDA | — | — | — | 57.2x | 35.3x | 23.2x | 19.3x | 37.9x | — | — | — | — |
Moderate moat
How hard Vanda Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median 15.5% of total assets over 6 years.
Gross margin has been a median 88.6%, moving by 9.4 percentage points (standard deviation) across 7 years.
Operating margin has been a median 1.6%; its worst year was -77.6%.
Free cash flow was positive in 6 of 10 years, at a median 10.8% of revenue.
The diluted share count rose 5.8% over five years; stock-based pay has been a median 6.0% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (54 before it).
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$3.01 | +20% | $242m | +12% |
| Next | −$1.00 | +67% | $317m | +31% |
The consensus EPS forecast for the current fiscal year is +32.7% on 90 days ago. In the last 30 days, 0 analysts raised Vanda Pharmaceuticals Inc.'s forecast and 4 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.27 | −$0.77 |
| 60 days ago | −$3.02 | −$1.03 |
| 30 days ago | −$3.03 | −$0.96 |
| 7 days ago | −$3.03 | −$0.96 |
| Now | −$3.01 | −$1.00 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Sept 2026 | −$0.68 | −$0.37 | +45.8% |
| Jun 2026 | −$0.59 | −$1.04 | −77.0% |
| Mar 2026 | −$0.69 | −$0.82 | −19.3% |
| Dec 2025 | −$1.32 | −$2.39 | −80.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −10.8%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $203m | $216m | +6.0% |
| P/S multiple | 1.3x | 1.1x | −14.5% |
| Share count | 59m | 59m | −1.6% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
Last 3 years −14.2%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $238m | $216m | −9.5% |
| P/S multiple | 1.1x | 1.1x | −1.9% |
| Share count | 57m | 59m | −3.3% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| VNDA | +19% | −53% | −43% | +14% | +84% | −56% |
| Industry peers (median) | −20% | −49% | −13% | −2% | +7% | −12% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| VNDA | 58% | 25% | 42% | 50% | 50% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| VNDA | −29% | −59% | −58% | −32% | −24% | −60% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 29, 2015: 89% from December 3, 2018 to November 9, 2023. Getting back needed a 831% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| October 28, 2026 | +1.5% | 0.0% | — | — |
| August 5, 2026 | −3.9% | −0.4% | −2.6% | +0.2% |
| May 6, 2026 | −13.5% | +1.1% | −13.0% | −18.4% |
| February 11, 2026 | −17.5% | −1.6% | −17.8% | +18.7% |
| October 29, 2025 | −22.6% | −1.1% | −20.4% | −3.9% |
| July 31, 2025 | −10.3% | −2.0% | −10.1% | +1.3% |
| May 7, 2025 | −3.4% | +1.1% | −10.3% | +5.5% |
| February 13, 2025 | −6.9% | +1.1% | −6.7% | +6.9% |
| November 6, 2024 | +4.8% | +3.3% | +14.0% | +1.0% |
| July 31, 2024 | −3.4% | +0.2% | −11.0% | −10.6% |
| May 8, 2024 | −8.6% | +0.6% | −2.2% | +11.7% |
| February 7, 2024 | +9.1% | +0.9% | +13.9% | +3.8% |
Source: SEC EDGAR filings. Retrieved October 30, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q4 | $192.6M |
| FY24 Q1 | $177.6M |
| FY24 Q2 | $182M |
| FY24 Q3 | $190.9M |
| FY24 Q4 | $198.8M |
| FY25 Q1 | $201.4M |
| FY25 Q2 | $203.5M |
| FY25 Q3 | $212.1M |
| FY25 Q4 | $216.1M |
| FY26 Q1 | $217.8M |
| FY26 Q2 | $215.7M |
| FY26 Q3 | $229.3M |
Source: SEC EDGAR filings. Retrieved October 30, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q4 | -24.3% |
| FY24 Q1 | -30.8% |
| FY24 Q2 | -23.6% |
| FY24 Q3 | -9.9% |
| FY24 Q4 | 3.2% |
| FY25 Q1 | 13.4% |
| FY25 Q2 | 11.8% |
| FY25 Q3 | 11.1% |
| FY25 Q4 | 8.7% |
| FY26 Q1 | 8.2% |
| FY26 Q2 | 6.0% |
| FY26 Q3 | 8.1% |
Source: SEC EDGAR filings. Retrieved October 30, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q4 | -7.2% |
| FY24 Q1 | -14.2% |
| FY24 Q2 | -17.8% |
| FY24 Q3 | -19.6% |
| FY24 Q4 | -20.5% |
| FY25 Q1 | -36.0% |
| FY25 Q2 | -49.5% |
| FY25 Q3 | -57.1% |
| FY25 Q4 | -70.0% |
| FY26 Q1 | -73.6% |
| FY26 Q2 | -86.1% |
| FY26 Q3 | -77.6% |
Source: SEC EDGAR filings. Retrieved October 30, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q4 | 6.4% |
| FY24 Q1 | -6.6% |
| FY24 Q2 | -3.0% |
| FY24 Q3 | -9.5% |
| FY24 Q4 | -8.2% |
| FY25 Q1 | -28.5% |
| FY25 Q2 | -32.4% |
| FY25 Q3 | -39.1% |
| FY25 Q4 | -51.1% |
| FY26 Q1 | -58.5% |
| FY26 Q2 | -66.3% |
| FY26 Q3 | -61.0% |
| Fiscal year | 2009 Dec 2009 | 2010 Dec 2010 | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Sept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||
| Revenue | 5 | 36 | 31 | 33 | 34 | 50 | 110 | 146 | 165 | 193 | 227 | 248 | 269 | 254 | 193 | 199 | 216 | 229 |
| EBITDA | −36 | 9 | −10 | −29 | −21 | 21 | −40 | −18 | −16 | 23 | 24 | 29 | 44 | 8 | −13 | −40 | −150 | −177 |
| Operating income | −36 | 9 | −11 | −29 | −21 | 20 | −40 | −19 | −17 | 22 | 23 | 27 | 42 | 6 | −14 | −41 | −151 | −178 |
| Net income | −36 | 7 | −10 | −29 | −21 | 20 | −40 | −18 | −16 | 25 | 116 | 23 | 33 | 6 | 3 | −19 | −220 | −275 |
| Diluted EPS | −$1.33 | $0.25 | −$0.35 | −$1.01 | −$0.69 | $0.55 | −$0.94 | −$0.41 | −$0.35 | $0.48 | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | −$0.33 | −$3.74 | −$4.59 |
| Growth (year on year) | ||||||||||||||||||
| Revenue | — | +685.2% | −12.4% | +4.7% | +3.5% | +48.0% | +119.2% | +32.8% | +13.1% | +17.0% | +17.6% | +9.2% | +8.3% | −5.3% | −24.3% | +3.2% | +8.7% | +8.1% |
| EBITDA | — | — | −211.6% | — | — | — | −292.3% | — | — | — | +4.4% | +18.3% | +52.1% | −82.7% | −272.7% | — | — | — |
| Operating income | — | — | −221.1% | — | — | — | −300.3% | — | — | — | +4.9% | +19.4% | +54.8% | −85.0% | −320.4% | — | — | — |
| Net income | — | — | −236.3% | — | — | — | −297.5% | — | — | — | +358.4% | −79.8% | +42.1% | −81.1% | −60.0% | — | — | — |
| Diluted EPS | — | — | −240.0% | — | — | — | −270.9% | — | — | — | +339.6% | −80.1% | +38.1% | −81.0% | −63.6% | — | — | — |
| Margins | ||||||||||||||||||
| EBITDA margin | −780.7% | 25.7% | −32.7% | −87.2% | −61.3% | 41.1% | −36.0% | −12.1% | −9.5% | 12.0% | 10.7% | 11.5% | 16.2% | 3.0% | −6.8% | −20.0% | −69.4% | −77.1% |
| Operating margin | −790.4% | 24.8% | −34.2% | −89.2% | −62.6% | 40.0% | −36.6% | −12.7% | −10.2% | 11.3% | 10.0% | 11.0% | 15.7% | 2.5% | −7.2% | −20.5% | −70.0% | −77.6% |
| Net margin | −788.5% | 20.1% | −31.3% | −87.4% | −62.1% | 40.2% | −36.3% | −12.3% | −9.4% | 13.1% | 50.9% | 9.4% | 12.3% | 2.5% | 1.3% | −9.5% | −102.0% | −119.9% |
| Free-cash-flow margin | — | — | −91.7% | −143.4% | −117.4% | −164.1% | 9.0% | −6.5% | −2.2% | 15.3% | 19.8% | 20.1% | 23.7% | 12.3% | 6.4% | −8.2% | −51.1% | −61.0% |
| Cash flow | ||||||||||||||||||
| Cash from operations | 169 | −11 | −28 | −45 | −40 | −82 | 12 | −8 | −2 | 30 | 46 | 52 | 64 | 32 | 13 | −16 | −109 | −139 |
| Capital spending | — | — | 0 | 2 | 0 | 1 | 3 | 1 | 2 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 1 |
| Free cash flow | — | — | −29 | −47 | −40 | −82 | 10 | −10 | −4 | 30 | 45 | 50 | 64 | 31 | 12 | −16 | −110 | −140 |
| Stock-based pay | 11 | 5 | 6 | 5 | 5 | 6 | 8 | 9 | 10 | 12 | 13 | 13 | 15 | 16 | 14 | 12 | 9 | 9 |
| Free cash flow after stock pay | — | — | −34 | −52 | −45 | −88 | 2 | −18 | −14 | 18 | 31 | 37 | 48 | 15 | −2 | −29 | −120 | −149 |
| Balance sheet | ||||||||||||||||||
| Cash | 205 | 43 | 88 | 89 | 65 | 61 | 51 | 40 | 34 | 61 | 45 | 61 | 52 | 135 | 136 | 102 | 85 | 62 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −205 | −43 | −88 | −89 | −65 | −61 | −51 | −40 | −34 | −61 | −45 | −61 | −52 | −135 | −136 | −102 | −85 | −62 |
| Diluted shares | 27m | 29m | 28m | 28m | 30m | 37m | 42m | 43m | 45m | 53m | 55m | 55m | 57m | 57m | 58m | 58m | 59m | 60m |
| Quarter | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 | 2026 Q3 Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 53 | 50 | 53 | 56 | 57 | 52 | 51 | 70 |
| EBITDA | −10 | −41 | −38 | −31 | −40 | −50 | −64 | −23 |
| Operating income | −10 | −41 | −39 | −31 | −40 | −50 | −64 | −24 |
| Net income | −5 | −29 | −27 | −23 | −141 | −49 | −63 | −23 |
| Diluted EPS | −$0.09 | −$0.50 | −$0.46 | −$0.38 | −$2.39 | −$0.82 | −$1.04 | −$0.37 |
| Growth (year on year) | ||||||||
| Revenue | +17.5% | +5.4% | +4.2% | +18.1% | +7.6% | +3.4% | −3.9% | +24.1% |
| Margins | ||||||||
| EBITDA margin | −18.9% | −81.5% | −72.7% | −55.1% | −70.0% | −96.6% | −125.8% | −33.3% |
| Operating margin | −19.3% | −82.0% | −73.2% | −55.6% | −70.5% | −97.1% | −126.3% | −33.7% |
| Net margin | −9.2% | −58.9% | −51.7% | −40.1% | −246.8% | −93.9% | −123.7% | −32.3% |
| Free-cash-flow margin | −3.8% | −67.1% | −29.6% | −56.5% | −51.6% | −97.5% | −61.9% | −41.2% |
| Cash flow | ||||||||
| Cash from operations | −2 | −33 | −15 | −32 | −29 | −50 | −31 | −28 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −2 | −34 | −16 | −32 | −30 | −50 | −31 | −29 |
| Stock-based pay | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 2 |
| Free cash flow after stock pay | −5 | −37 | −18 | −34 | −32 | −53 | −33 | −31 |
| Last 12 months unless stated | VNDA | ACB | HROW | OGI | BTMD | KMDA | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $229m | $232m | $276m | $185m | $184m | $180m | $276m |
| Revenue growth, last 12 months | 8.1% | 11.7% | 21.1% | 57.8% | −7.8% | 12.1% | 9.9% |
| Revenue growth, 3-year average | 2.7% | — | 39.0% | — | 0.5% | — | 5.5% |
| Revenue growth, latest quarter | 24.1% | — | 10.9% | — | −9.5% | — | 6.5% |
| Gross margin | 90.0% | 42.6% | 73.3% | 34.8% | — | 42.3% | 62.0% |
| Operating margin | −77.6% | 1.9% | −1.0% | −5.9% | 8.0% | 14.5% | −5.9% |
| Operating margin, 3-year average | −51.4% | — | −0.1% | — | 13.9% | 7.0% | −7.4% |
| Net margin | −119.9% | −42.4% | −13.5% | −9.6% | 3.2% | 11.2% | −7.3% |
| Cash from operations / revenue | −60.7% | −4.2% | 2.3% | −2.9% | 13.3% | 14.1% | 10.2% |
| Free-cash-flow margin | −61.0% | −5.4% | 1.8% | −9.5% | 10.8% | 13.2% | 8.6% |
| Free-cash-flow margin, 3-year average | −36.6% | — | 0.8% | — | 13.2% | 1.7% | 7.4% |
| Stock pay / revenue | 4.1% | 2.3% | 5.3% | 1.6% | 4.5% | 0.5% | 3.6% |
| Change in share count | 1.8% | 3.0% | 0.5% | 34.0% | 3.3% | 0.9% | 1.9% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 8.1% | 10.0% | 41 of 74 |
| Change in growth rate Growth | +2.1pp | -0.3pp | 23 of 74 |
| Operating margin Profitability | -77.6% | -5.9% | 52 of 67 |
| Net margin Profitability | -119.9% | -7.3% | 63 of 75 |
| Free-cash-flow margin Cash generation | -61.0% | 10.1% | 63 of 74 |
| Stock pay as % of revenue Cash generation | 4.1% | 3.6% | 38 of 69 |
| Change in share count Balance sheet | 1.8% | 1.5% | 34 of 62 |
| Days sales outstanding Balance sheet | 96 days | 72 days | 44 of 59 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Fanapt | $117M | 54.3% | ▲ 24.4% |
| Hetlioz | $71.4M | 33.1% | ▼ 6.8% |
| PONVORY | $27.4M | 12.7% | ▼ 1.5% |
From Vanda Pharmaceuticals Inc.'s 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $46.8M | 7.7M | 15.4% | ▲ 5.2% |
| State Street Corp | $21.5M | 3.5M | 7.1% | ▲ 16.6% |
| AQR Capital Management LLC | $21.4M | 3.5M | 7.0% | ▲ 118.1% |
| Renaissance Technologies LLC | $21.1M | 3.4M | 6.9% | ▼ 8.5% |
| Vanguard Capital Management LLC | $15.4M | 2.5M | 5.1% | ▲ 1.7% |
| Aigh Capital Management LLC | $12.5M | 2.0M | 4.1% | ▼ 25.7% |
| Acadian Asset Management LLC | $11.7M | 1.9M | 3.9% | ▲ 6.8% |
| Dimensional Fund Advisors LP | $10.6M | 1.7M | 3.5% | ▼ 2.5% |
| Millennium Management LLC | $9.8M | 1.6M | 3.2% | ▼ 14.8% |
| Geode Capital Management, LLC | $9.1M | 1.5M | 3.0% | ▲ 2.8% |
| Two Sigma Investments, LP | $8.3M | 1.3M | 2.7% | ▼ 3.5% |
| Marshall Wace, LLP | $7.5M | 1.2M | 2.5% | ▲ 105.7% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Vanda Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Birznieks Gunther SVP, Business Development | March 2, 2026 | Sell | 42,431 | $8.27 | $350,730 |
| Polymeropoulos Mihael Hristos President and CEO | March 2, 2026 | Sell | 156,235 | $8.17 | $1.3M |
| Wijkstrom Joakim SVP, Chief Marketing Officer | March 2, 2026 | Sell | 30,800 | $8.27 | $254,590 |
| Moran Kevin Patrick SVP, CFO & Treasurer | March 2, 2026 | Sell | 42,442 | $8.27 | $350,821 |
| Williams Timothy SVP & General Counsel | March 2, 2026 | Sell | 42,434 | $8.27 | $350,755 |
| Honore Tage Director | February 23, 2026 | Sell | 30,000 | $8.03 | $240,900 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around February 10, 2027 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
